Feline Renal Lymphoma

Feline renal lymphoma is a malignant neoplasm arising from lymphoid tissue within one or both kidneys, representing one of the most clinically significant presentations of feline lymphoma. Lymphoma is the most common hematopoietic malignancy in cats, and renal involvement may occur as a primary, isolated form or as a component of multicentric disease [1]. The condition can affect cats of any age, though older cats are more commonly diagnosed, and it has also been recognized as a notable complication in cats receiving renal transplants and associated immunosuppressive therapy [6]. Given its capacity to cause rapidly progressive renal failure and systemic illness, early recognition and prompt intervention are critical to optimizing patient outcomes.

The precise etiology of feline renal lymphoma remains incompletely understood, though several predisposing factors and mechanisms have been identified.

Viral Associations: Feline Leukemia Virus (FeLV) has historically been associated with lymphoma development in cats; however, the proportion of FeLV-positive renal lymphoma cases has declined over time, likely reflecting widespread FeLV vaccination programs [1]. Feline Immunodeficiency Virus (FIV) may also indirectly increase lymphoma risk through chronic immune dysregulation.

Immunosuppression: A compelling association exists between iatrogenic immunosuppression and renal lymphoma. Cats receiving renal transplants and subsequent immunosuppressive therapy (typically cyclosporine and prednisolone) demonstrate a markedly increased incidence of post-transplantation lymphoma, with the kidney being a common site of involvement [6]. This mirrors the well-documented increased lymphoma risk in human transplant recipients and strongly implicates immune surveillance failure in lymphomagenesis [6].

Co-morbid Conditions: Concurrent systemic illness can complicate the clinical picture. A notable case report described a young cat diagnosed simultaneously with feline infectious peritonitis (FIP) and renal lymphoma, underscoring that immune dysregulation or inflammatory states may permit concurrent or coincidental neoplastic transformation [2].

Pathological Mechanism: Neoplastic lymphocytes infiltrate renal parenchyma, disrupting normal nephron architecture and function. This infiltration leads to progressive replacement of functional renal tissue, resulting in azotemia, loss of urine concentrating ability, and ultimately renal failure. The neoplastic cells may also secrete paraneoplastic mediators — notably parathyroid hormone-related protein (PTHrP) — causing humoral hypercalcemia of malignancy, which itself further damages remaining nephrons through calcium deposition [5]. The disease may remain confined to the kidneys or disseminate to other organs including lymph nodes, liver, spleen, bone marrow, and the central nervous system [1].

Diagnosis of feline renal lymphoma requires integration of clinical findings, laboratory data, diagnostic imaging, and cytological or histopathological confirmation.

Physical Examination: Bilateral or unilateral renomegaly is a key finding; affected kidneys may feel enlarged, irregular, or nodular on abdominal palpation [2][1].

Laboratory Findings:

• ·Complete Blood Count (CBC): Anemia (typically normocytic, normochromic, non-regenerative) is common [7]; leukocyte counts may be variable; circulating neoplastic lymphocytes are occasionally identified.
• ·Serum Biochemistry:
  • ·BUN and CREA (creatinine): Elevated, reflecting reduced glomerular filtration rate due to parenchymal replacement [7]
  • ·Phosphorus: Often elevated in conjunction with azotemia
  • ·Calcium (total and ionized): May be elevated in paraneoplastic hypercalcemia [5]
  • ·ALB (albumin): May be low due to protein-losing nephropathy or reduced hepatic synthesis
  • ·GLOB (globulins): May be elevated in cases with concurrent inflammatory disease
  • ·ALT: May be elevated if hepatic involvement is present
  • ·Potassium: Hypokalemia possible in cats with polyuric renal disease
• ·Urinalysis: Isosthenuria or minimally concentrated urine is typical; proteinuria may be present. Crucially, one case report demonstrated that Wright-Giemsa-stained cytocentrifuged urine sediment examination revealed neoplastic lymphocytes, offering a minimally invasive avenue for diagnosis in cats with renal lymphoma [7].
• ·SDMA: An early renal biomarker that may be elevated prior to creatinine reaching azotemic thresholds.

Diagnostic Imaging:

• ·Abdominal Ultrasonography: The primary imaging modality. Renal lymphoma typically produces diffuse or multifocal hypoechoic changes within the renal cortex and medulla, loss of normal corticomedullary distinction, and marked renomegaly [3]. Both kidneys are frequently affected [1]. Ultrasound also guides fine-needle aspiration (FNA).
• ·Radiography: May demonstrate nephromegaly or abdominal mass effect; less specific than ultrasound.
• ·CT/Advanced Imaging: Increasingly utilized for staging and surgical planning.

Cytology and Histopathology:

• ·Fine-Needle Aspiration (FNA): Ultrasound-guided renal FNA is a rapid and relatively non-invasive means of obtaining diagnostic material; renal cytology can identify lymphoid infiltrates consistent with lymphoma [4]. Cytological samples typically reveal a monomorphic population of lymphocytes (often large, immature forms in high-grade disease).
• ·Histopathology: Core needle biopsy or surgical biopsy provides tissue architecture and allows for definitive classification (e.g., large B-cell vs. T-cell lymphoma) and immunohistochemical subtyping.
• ·Urine Cytology: As noted above, examination of cytocentrifuged urine sediment may occasionally reveal shed neoplastic lymphocytes, providing a non-invasive diagnostic clue [7].
• ·Flow Cytometry / PARR (PCR for Antigen Receptor Rearrangement): May be applied to FNA or biopsy samples to confirm clonality and immunophenotype.

Staging: Complete staging should include thoracic radiographs, abdominal ultrasound, bone marrow evaluation, and possibly lymph node aspirates to determine whether disease is localized (renal) or multicentric [1].

Treatment of feline renal lymphoma is primarily chemotherapy-based, with supportive care playing an essential ancillary role. Curative intent is challenging, and the goal is often remission and quality of life [1][2].

Chemotherapy:

• ·COP Protocol (Cyclophosphamide, Vincristine [Oncovin], Prednisolone): A common multi-agent protocol used in feline lymphoma; may be used in cats with compromised renal function where more aggressive protocols are not tolerated.
• ·CHOP-based Protocols (Cyclophosphamide, Doxorubicin [Hydroxydaunorubicin], Vincristine [Oncovin], Prednisolone): More aggressive protocols used when renal function permits; doxorubicin adds meaningful efficacy for high-grade lymphoma. However, doxorubicin carries nephrotoxic potential, which must be carefully weighed in cats already experiencing renal dysfunction [1].
• ·Chlorambucil with Prednisolone: May be employed in low-grade presentations or in cats unable to tolerate more intensive protocols.
• ·Single-Agent Protocols: In debilitated patients, single-agent or reduced-intensity protocols may be used to balance efficacy and tolerability.

Novel and Emerging Therapies: In cases involving concurrent FIP, antiviral therapy (e.g., GS-441524 or molnupiravir) may be administered alongside or sequentially with lymphoma chemotherapy, as demonstrated in at least one case where FIP remission was achieved alongside lymphoma treatment [2].

Supportive Care:

• ·Intravenous fluid therapy: Essential for correcting dehydration, supporting renal perfusion, and managing azotemia prior to chemotherapy initiation.
• ·Anti-emetics: Maropitant or ondansetron for chemotherapy-induced nausea and vomiting.
• ·Appetite stimulants: Mirtazapine or capromorelin to address hyporexia.
• ·Phosphate binders and renal diet: To manage hyperphosphatemia associated with concurrent renal insufficiency.
• ·Management of hypercalcemia: Saline diuresis, bisphosphonates, or glucocorticoids if paraneoplastic hypercalcemia is present [5].

Post-Transplant Lymphoma: In cats that develop renal lymphoma following renal transplantation, reduction or modification of immunosuppressive therapy may be considered alongside standard lymphoma chemotherapy, mirroring strategies employed in human post-transplant lymphoproliferative disorder [6].

Prognosis for feline renal lymphoma is generally guarded to poor, reflecting both the advanced renal dysfunction often present at diagnosis and the aggressive behavior of many renal lymphoma subtypes [1].

Survival Data: Williams et al. (2021) conducted a retrospective study of 27 feline renal lymphoma cases, providing the most current dedicated dataset on this condition [1]. This study described outcomes related to renal lymphoma including clinical presentation, therapeutic approaches, and survival times, highlighting that outcomes vary significantly based on disease extent (localized vs. multicentric), immunophenotype, and treatment received [1]. Prior to this work, outcomes had not been systematically reported since Mooney et al. in 1987 [1].

Key Prognostic Factors:

• ·Disease extent: Cats with isolated renal involvement may fare better than those with multicentric dissemination [1].
• ·Renal function at diagnosis: Severe azotemia at presentation is a negative prognostic indicator, limiting tolerance of aggressive chemotherapy.
• ·Histological grade and immunophenotype: High-grade (large cell) lymphoma carries a significantly worse prognosis than low-grade disease; B-cell phenotype is generally associated with better response to treatment compared with T-cell in many studies.
• ·Response to initial chemotherapy: Achievement of complete remission is associated with longer survival times.
• ·Concurrent disease: Presence of comorbidities such as FIP may complicate treatment but, as illustrated in one case, successful concurrent management of both conditions is possible in some patients, with documented long-term follow-up [2].

General Expectations: Feline lymphoma as a disease class carries a serious prognosis, and achieving a true cure with chemotherapy is considered questionable [2]. Median survival times reported across feline lymphoma studies are often measured in months, with high-grade forms carrying median survivals of weeks to a few months without treatment. With multi-agent chemotherapy, some cats achieve remission durations of several months to over a year, though long-term data specific to the renal form remain limited [1].

There are no specific, evidence-based preventive measures that completely eliminate the risk of feline renal lymphoma. However, several strategies may reduce overall risk:

Vaccination and Viral Disease Control:

• ·FeLV Vaccination: Since FeLV is associated with lymphoma development in cats, adherence to FeLV vaccination protocols — especially for cats with outdoor access or exposure to other cats — is a reasonable risk-reduction strategy [1].
• ·FeLV and FIV Testing: Regular testing of at-risk cats and management of positive individuals (including preventing transmission to other cats) reduces the population-level burden of retroviral-associated lymphoma.

Post-Transplant Monitoring:

• ·Cats receiving renal transplants should undergo regular oncologic monitoring given their substantially elevated lymphoma risk due to prolonged immunosuppression [6]. Early detection through periodic physical examination, bloodwork, urinalysis, and ultrasonography may allow for earlier intervention.
• ·Judicious use of immunosuppressive agents and the lowest effective dose to prevent rejection may reduce, though not eliminate, post-transplant lymphoma risk [6].

General Health Management:

• ·Routine veterinary check-ups with periodic abdominal palpation, urinalysis, and blood panels facilitate early detection of renomegaly or early renal dysfunction.
• ·Minimizing exposure to potential environmental carcinogens (tobacco smoke, certain pesticides) is prudent general oncology advice, though direct causative links to renal lymphoma in cats are not firmly established.

Screening of High-Risk Populations:

• ·Older cats and those with known immunosuppressive conditions should have more frequent wellness evaluations to enable earlier diagnosis.

**